Benimetskaya, Luba and Wu, Sijian and Voskresenskiy, Anatoliy M. and Echart, Cinara and Zhou, Jin-Feng and Shin, Joongho and Iacobelli, Massimo and Richardson, Paul and Ayyanar, Kanyalakshmi and Stein, C. A. (2008) Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. BLOOD, 112 (10). pp. 4343-4352. ISSN Online ISSN: 1528-0020
Full text is not hosted in this archive but may be available via the Official URL, or by requesting a copy from the corresponding author.
Official URL: http://bloodjournal.hematologylibrary.org/cgi/cont...
Defibrotide (DF) is a mixture of porcine-derived single-stranded phosphodiester oligonucleotides (9-80-mer; average, 50-mer) that has been successfully used to treat severe hepatic veno-occlusive disease (sVOD) with multiorgan failure (MOF) in patients who have received cytotoxic chemotherapy in preparation for bone marrow transplantation. However, its mechanism of action is unknown. Herein, we show that DF and phosphodiester oligonucleotides can bind to heparin-binding proteins (eg, basic fibroblast growth factor [bFGF] but not vascular endothelial growth factor [VEGF] 165) with low nanomolar affinity. This binding occurred in a length- and concentration-dependent manner. DF can mobilize proangiogenic factors such as bFGF from their depot or storage sites on bovine corneal endothelial matrix. However, these molecules do not interfere with high-affinity binding of bFGF to FGFR1 IIIc but can replace heparin as a required cofactor for binding and hence cellular mitogenesis. DF also protects bFGF against digestion by trypsin and chymotrypsin and from air oxidation. In addition, DF binds to collagen I with low nanomolar affinity and can promote human microvascular endothelial cell-1 (HMEC-1) cell mitogenesis and tubular morphogenesis in three-dimensional collagen I gels. Thus, our data suggest that DF may provide a stimulus to the sinusoidal endothelium of a liver that has suffered a severe angiotoxic event, thus helping to ameliorate the clinical sVOD/MOF syndrome. (Blood. 2008; 112: 4343-4352)
|Subjects:||Biomedical Science > Nanotechnology for human health|
|Deposited By:||M T V|
|Deposited On:||04 Dec 2008 15:25|
|Last Modified:||04 Dec 2008 15:25|
Repository Staff Only: item control page